What really happens when you stop GLP-1 medications — and are the headlines telling you the whole story? The answer is more nuanced than social media wants you to believe.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down four recent studies on GLP-1 treatment outcomes, weight regain, and a groundbreaking new drug that could preserve lean mass during treatment. They walk through the methodology behind each paper, explain why two studies asking the same question got opposite answers, and reveal what a new monoclonal antibody called bimagrumab could mean for the future of metabolic treatment.

Key Takeaways

• When you stop treating any chronic metabolic condition, the condition returns — that's not failure, that's biology.

• Real-world data showed 56% of people who stopped filling GLP-1 prescriptions maintained or continued losing weight — likely because they continued working with their clinician on alternative treatments.

• A new monoclonal antibody called bimagrumab showed 11% body weight reduction on its own, while simultaneously increasing lean mass by 3% — without affecting appetite.

• When combined with semaglutide, bimagrumab reduced lean mass loss from 28% to just 11% of total weight lost.

• Not eating enough while on GLP-1s drives greater lean mass loss — nutrition is still the best tool for preserving muscle.

Notable Quote

"It wasn't my failure and it was disease underneath everything. Finding that out — that it wasn't my fault — that was the miracle of the whole process to me." — Andrea Taylor

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Join Our Community: patreon.com/cw/FatSciencePodcast

• Submit Your Question: [email protected] or [email protected]

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations

Ever wonder why fasting worked at first — then stopped? Or why you lost 80 pounds only to gain back 100?

In this mailbag episode, Dr. Emily Cooper, Mark Wright, and Andrea Taylor tackle the most misunderstood topics in metabolic health. From the harsh reality of fasting culture to the surprising metabolic challenges faced by normal-weight individuals, this conversation validates what you've been experiencing and explains the science behind it. You'll also hear why GLP-1 medications aren't just weight loss drugs, why your body might be fighting you even when you're doing everything right, and what happens when your job — like shift work or firefighting — disrupts your metabolism for years.

KEY TAKEAWAYS

• You can have metabolic dysfunction at a normal weight with what appear to be normal labs, for example, when insulin is over suppressed from chronic under-fueling or overexercising
• Fasting triggers the same biological adaptation as any restrictive diet and typically results in weight regain that's 22 percent higher than starting weight
• Food noise is biological, not psychological, and stems from an imbalance of hormones and neurotransmitters signaling nutritional insecurity
• GLP-1 medications may improve immune function because metabolic health and immunity are deeply connected
• Shift work and chronic sleep disruption can cause real metabolic damage by weakening leptin signals, increasing insulin resistance, and amplifying hunger hormones

NOTABLE QUOTE

"You can't trick your body. You have to have that foundational fueling in there." — Dr. Emily Cooper

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Are you getting eight hours in bed but still waking up exhausted?

Dr. Emily Cooper shares groundbreaking findings from nearly 15,000 patient encounters at her metabolic clinic. The data reveals surprising connections between stress, eating frequency, sleep quality, and metabolic health — and why the number of hours you spend in bed doesn't tell the whole story.

KEY TAKEAWAYS

• Over 60% of patients reported trouble staying asleep, even when they got eight hours in bed
• Higher stress levels were associated with double the rate of low energy and significantly worse sleep quality
• Eating frequency matters — patients eating five times per day reported the best sleep and highest energy levels
• The sweet spot between meals is two to four hours — longer gaps were linked to sleep disruption and low energy
• Any amount of alcohol was associated with fragmented sleep, regardless of stress levels
• Nearly 65% of patients were not hydrating adequately throughout the day

NOTABLE QUOTE

"If your cortisol goes high, we can get the same effects that happen when we take steroids, which we know promote pre-diabetes, insulin resistance, weight gain." — Dr. Emily Cooper

Links & Resources

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Think squashing your post-meal glucose spike is the healthy thing to do? What if that flat line on your CGM is actually telling your brain you didn't eat — and slowing your metabolism as a result?

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor open the mailbag to tackle listener questions from around the world — Australia, New Zealand, and across the U.S. They dig into hormone replacement therapy and metabolism, why your GLP-1 medication might be causing hair loss, what a normal blood sugar response actually looks like, and how lipedema differs from obesity. Dr. Cooper also revisits metabolic syndrome and why it's not outdated — just underutilized.

Key Takeaways

• Hormone replacement therapy isn't a reliable tool for improving metabolism — it's better suited for symptom relief and bone health in specific situations.

• Progesterone, which must accompany estrogen if you still have your uterus, can actually disrupt metabolism in some women — acting almost like a steroid.

• A flat glucose line after eating isn't the goal — your brain needs to see glucose go up to register that you've been nourished and keep your metabolism running.

• Hair loss on GLP-1 medications is more likely tied to nutrient deficiencies (especially iron and protein) than the drugs themselves.

• Lipedema is a disease of the fat tissue itself — separate from obesity — and tirzepatide may help reduce the inflammatory symptoms even though it won't eliminate the fat deposits.

Notable Quote

"If your glucose is flat line, your brain's not very convinced that you ate much — and then you're not getting the metabolic benefit." — Dr. Emily Cooper

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Join Our Community: patreon.com/cw/FatSciencePodcast

• Submit Your Question: [email protected] or [email protected]

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

What happens when you do everything "right" — the GLP-1, the protein shake, the tracking — and the scale still won't budge? This episode reveals why doing everything “right” might actually be a big part of the problem.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor welcome Sandy, a listener from Pennsylvania who has been on the metabolic health journey for over a year. Sandy's story is one many listeners will recognize: decades of dieting starting in childhood, a body that kept adapting against her, and a medical system that kept telling her to try harder. But when Dr. Cooper reviews Sandy's actual lab work live on air, what she finds reframes everything — and offers a path forward that has nothing to do with restriction.

Key Takeaways

• Suppressed leptin hides a portion of your body fat from your brain, and possibly signals your brain that you're underweight — so your brain fights weight loss even when your body doesn't need protecting.

• Low insulin isn't always healthy; it can be a sign of the "selfish brain" redirecting precious glucose to the brain at the expense of your muscles.

• Weight cycling — losing and regaining the same weight repeatedly — creates cardiovascular and metabolic risk.

• Mechanical eating is the antidote to disordered eating: structured, non-restrictive fueling that rebuilds metabolic trust.

• GLP-1 medications can suppress appetite, so under-eating becomes a real risk — especially for people already conditioned to restrict.

• The goal isn't the number on the scale. It's metabolic stability and metabolic health, and those things are not the same.

Notable Quote

"It was such a revelation to me to hear you guys talk about it — it's a metabolic disorder. It's not a willpower issue, it's not a personal failing. It's something absolutely beyond my control. Like diabetes would be. Like migraines would be." — Sandy

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Join Our Community: patreon.com/cw/FatSciencePodcast

• Submit Your Question: [email protected] or [email protected]

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

The Science Behind the New Wegovy Pill (with Novo Nordisk’s Dr. Jason Brett)

What actually makes a GLP-1 pill work in the real world—and why does taking it come with such specific rules? And if these meds improve health beyond weight, why does the conversation still get stuck on the scale?

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor are joined by Dr. Jason Brett of Novo Nordisk to break down the science behind the newly approved Wegovy pill. They talk about what it takes to deliver a peptide medication orally, what the dosing and day-to-day routine really look like, and why access and pricing remain such a big part of the story. The conversation also zooms out to the bigger point: treating obesity is about improving health outcomes—like liver and cardiovascular risk—not just weight.

Key Takeaways

• Oral semaglutide requires specific formulation technology to survive the stomach and be absorbed at a meaningful level.

• The “30-minute rule” isn’t random—it’s part of how the pill has a chance to work as intended.

• Treating obesity is about improving health outcomes (like liver and heart risk), not just “moving a number on a scale.”

• Pricing and access shape who can actually benefit, even when the science is strong.

• Calorie-restriction messaging can backfire for people already dealing with metabolic adaptation and under-nutrition.

Notable Quote

"Fat Science has no financial relationship with Novo Nordisk. No sponsorship. No consulting fees, no affiliate arrangements. Zero." — Mark Wright

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Join Our Community: patreon.com/cw/FatSciencePodcast

• Submit Your Question: [email protected] or [email protected]

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Mailbag: Your GLP-1 Questions on Pregnancy, Dosing, and Why Diets Cause Fat Gain

What happens when you stop GLP-1 medications before getting pregnant? Why might your thyroid numbers change on Zepbound? And why do people gain more body fat after dieting — even when they're still eating well? Dr. Cooper tackles your toughest questions.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener questions covering pregnancy planning on GLP-1s, unmasked thyroid problems, injection site reactions, mechanical eating after bariatric surgery, why diets cause fat regain at a cellular level, and discussing with your doctor whether you should (or shouldn't) increase your medication dose.

Key Takeaways

• GLP-1 medications aren't causing gestational diabetes — they may have been masking underlying metabolic dysfunction that becomes visible when the medication is stopped

• Thyroid problems can be "unmasked" by GLP-1 treatment because the medications signal to your brain that you're not starving, allowing the pituitary TSH to rise, sometime uncovering a pre-existing thyroid issue

• Zepbound may improve iron absorption — if iron levels go too high, testing for hemochromatosis may be warranted

• To reduce injection site reactions: warm the medication to room temperature, clean and prep skin but don't over-rub with alcohol, inject at exactly 90 degrees, don't pinch the skin, and stay relaxed

• Diets cause fat regain at the cellular level — it's chemistry, not willpower — and the fat often accumulates in the visceral area around organs

• There's no need to increase your GLP-1 dose if you're making good progress — an annual weight loss rate of 15% or higher is considered strong

Notable Quote

"You can't think that just because somebody's weight is high, it's because something they're doing is wrong. That is just not founded in science whatsoever." — Dr. Emily Cooper

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Join Our Community: patreon.com/cw/FatSciencePodcast

• Submit Your Question: [email protected] or [email protected]

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Wegovy Pill: Who's It For?

The new Wegovy pill is generating massive buzz — but is it actually better than the injection? Before you ask your doctor to switch, there are some surprising requirements that could make or break whether this option works for you.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down the new oral semaglutide approved for obesity treatment. They explain how the Wegovy pill differs from Rybelsus, who's a good candidate to switch (and who isn't), the strict dosing protocol most people don't know about, and what's coming next in the GLP-1 pill landscape — including a less fussy competitor from Eli Lilly.

Key Takeaways

• The Wegovy pill uses an upgraded "version two" formulation with enhanced absorption — it's not the same as Rybelsus

• Semaglutide targets deep metabolic dysfunction, not just appetite — reducing inflammation, visceral fat, and cardiovascular risk

• The pill must be taken first thing in the morning on an empty stomach with minimal water, then nothing else for 30 minutes — breaking this protocol negates effectiveness

• The pill is slightly less effective than the highest-dose Wegovy injection, so switching isn't ideal for patients still making progress at maximum dose

• Novo Nordisk's cash pay program starts at $149/month for lower doses and $299/month for the highest dose

• Eli Lilly's upcoming orforglipron pill uses small molecule technology that won't require the strict dosing ritual

Notable Quote

"When people say it works because it just makes you eat less, that's really missing the point of the sophistication of these meds." — Dr. Emily Cooper

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Join Our Community: patreon.com/cw/FatSciencePodcast

• Submit Your Question: [email protected] or [email protected]

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

What if the scale isn't moving, but your health is dramatically improving?

If you've ever felt discouraged because the number on the scale won't budge—even on a GLP-1 medication—this episode will change how you think about these drugs. Dr. Cooper breaks down the research showing that the biggest benefits have nothing to do with weight loss. It's all about metabolic health.

This Week on Fat Science

Dr. Emily Cooper, Mark Wright, and Andrea Taylor explore the research proving GLP-1 medications are far more than "weight loss drugs." The team explains how cardiovascular outcome trials revealed unexpected heart protection, why inflammation reduction may be the real mechanism behind these benefits, and what the latest FDA approvals for kidney disease, sleep apnea, and fatty liver mean for patients. Plus: the new oral Wegovy pill, what's coming next in metabolic medicine, and why everyone should be screened for metabolic dysfunction regardless of weight.

What You'll Learn

• Why two-thirds of cardiovascular risk reduction from GLP-1s is completely independent of weight loss

• How these medications reduce inflammation, stabilize arterial plaque, and improve vascular function

• The difference between MASLD and MASH—and why the name change matters

• What the Flow Trial revealed about kidney protection (and why it was stopped early)

• How Zepbound earned FDA approval for sleep apnea

• Why metabolic screening should happen regardless of what the scale says

Notable Quote

"You can still become incredibly healthier even if the weight is more stubborn. So I think that's the thing, is to discuss with your doctor not 'Oh, I want to lose X amount of pounds' or 'How much weight do you think I should lose?' That is not the conversation. It's more, let's take a look at the health parameters."

— Dr. Emily Cooper

Links & Resources

• Podcast Home: fatsciencepodcast.com

• Cooper Center for Metabolism: coopermetabolic.com

• Resources from Dr. Cooper: coopermetabolic.com/resources

• Submit Your Question: [email protected] or [email protected]

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener mailbag questions from California, the UK, France, Washington, Wyoming, and beyond. 

The team breaks down why Dr. Cooper does not recommend calorie tracking (and when limited tracking can make sense), how to build confidence in eating without data, and why “mechanical eating” sometimes needs medical customization—especially for people with slow gut transit or gastroparesis-like symptoms. 

They also dig into bile acid malabsorption after gallbladder removal, when metformin side effects deserve a second look, what we currently know about COVID-19’s potential impact on metabolic health, and why metformin and GLP-1 medications can be complementary—particularly in PCOS.

Key Takeaways
• Long-term calorie tracking can override physiologic cues and reinforce diet mentality.
• Short-term, targeted tracking may be useful when guided by a clinician (e.g., nutrient deficiencies ).
• Obesity and abnormal appetite are both manifestations of metabolic dysfunction—not simple cause and effect.
• Mechanical eating is a framework, not a rigid rule—timing and food choices may need medical tailoring.
• Post-gallbladder diarrhea may reflect bile acid malabsorption and can be treatable.
• Metformin and GLP-1s often complement each other because they target different metabolic states (fasting vs fed).

Dr. Cooper’s Actionable Tips
• Stop daily calorie counting—focus on consistent patterns and metabolic nourishment.
• Use mechanical eating basics: eat every few hours, include all food groups, and reduce chemical additives when possible.
• If you’re transitioning away from tracking, consider a dietitian skilled in diet-mentality recovery.
• If frequent eating worsens sleep or bloating, work with a medical dietitian to adjust intervals and food types (especially with slow GI transit).
• If chronic diarrhea appears (especially after gallbladder removal), ask your clinician about bile acid malabsorption and treatment options.
• Use labs to guide therapy: fasting insulin can signal metformin benefit; post-meal patterns can point toward GLP-1 needs.

Notable Quote
“Once you start using tracking to stay in a calorie range or a carbohydrate range, you’re putting your brain in front of your physiologic intuition—your body is sending you important cues all the time.”
—Dr. Emily Cooper

Links & Resources

The Metabolic Links to PCOS, Release Date 2/24/25

The COVID Connection to Diabetes & Metabolic Health, Release Date 12/16/24

Podcast Home: https://fatsciencepodcast.com/
Episode References: https://fatsciencepodcast.com/wp-content/uploads/2025/06/Scientific-References-Fat-Science-Episodes.pdf
Cooper Center: https://coopermetabolic.com/podcast/
Resources from Dr. Cooper: https://coopermetabolic.com/resources/
Submit a Question: [email protected]

*Fat Science: No diets, no agendas—just science that makes you feel better. This podcast is for informational purposes only and is not intended to be medical advice.